

IN THE CLAIMS

1-26. (canceled)

27. (previously presented) An *in vitro* method of treating a neoplastic cell, comprising:

administering to the cell a therapeutically effective amount of antisense oligonucleotides which are complementary to human MDM2 mRNA and which inhibit transcription or translation of a human MDM2 gene.

28. (original) The method of claim 27 wherein expression of the human MDM2 gene is inhibited by administering antisense oligonucleotides.

29-55. (canceled)

56. (previously presented) An *in vitro* method of treating a cell having an amplified human MDM2 gene, elevated expression of human MDM2 mRNA, or elevated expression of human MDM2 protein, comprising:

administering to the cell a therapeutically effective amount of antisense oligonucleotides which are complementary to human MDM2 mRNA and which inhibit transcription or translation of a human MDM2 gene.

57-61. (canceled)

62. (new) An *in vitro* method of interfering with expression of MDM2 comprising administering to a neoplastic cell an antisense oligonucleotide which is complementary to human MDM2 mRNA in an amount effective to interfere with expression of MDM2.

63. (new) An *in vitro* method of interfering with expression of MDM2 comprising administering to a cell having an amplified human MDM2 gene, elevated expression of human

MDM2 mRNA, or elevated expression of human MDM2 protein an antisense oligonucleotide which is complementary to human MDM2 mRNA in an amount effective to interfere with expression of MDM2.